key: cord-0760048-5y5snffy
authors: Gisbert, Guillem Llopis; Urrutia, Verónica Vidal; Moruno Benita, Miguel A.; Chaume, Ana Payá; Jofresa, Alberto Berenguer; Cubillos Arango, Andrés M.; Pérez Boscá, José L.; Serrano, Rafael Payá
title: Bioprosthetic valve thrombosis and obstruction secondary to COVID-19
date: 2020-10-24
journal: Can J Cardiol
DOI: 10.1016/j.cjca.2020.10.008
sha: 0f8fbf3cc0df66cf5673edc0669aae0637edcf2d
doc_id: 760048
cord_uid: 5y5snffy

Patients with COVID-19 may present a hypercoagulable state, with an important impact on morbidity and mortality. Because of this situation pulmonary embolism is a frequent complication during the course of infection. We present the case of a patient recently discharged, after admission with confirmed COVID-19, who developed a pulmonary embolism and thrombosis of a biological mitral valve prosthesis, producing valve obstruction and stenosis. After 15 days of anticoagulant treatment, resolution of the thrombus and normalization of prosthetic valve function was observed. This case supports current recommendations of administering full-dose anticoagulation therapy to COVID-19 patients with biological heart valve prosthesis, even after the acute phase of infection.

for laboratory findings). We At hospital discharge, we switched to oral anticoagulation with vitamin K antagonist (acenocoumarol) for an INR goal of 3-3.5, bridging with heparin. We Related to the topic of COVID-19-associated heart valve prostheses thrombosis, we performed a literature review and did not find any cases reporting mechanical or biological prostheses thrombosis. Typically, bioprosthetic valve thrombosis is a possible but infrequent finding. In the case we present the patient had a biological mitral prosthesis thrombosis simultaneously with PE. Making the correct diagnosis was required to provide J o u r n a l P r e -p r o o f the patient with the optimal anticoagulation strategy, after which we verified the resolution of the thrombus and consequently of the prosthetic valve stenosis.

Finally, we conclude that patients with COVID-19 may present hypercoagulability causing the occurrence of pulmonary thromboembolism and in some cases also thrombosis of heart valve prostheses, as was the case of our patient two weeks after hospital discharged for COVID 19 pneumonia. With these findings, we support the recommendation of a prolonged anticoagulation strategy at full therapeutic doses after discharge of selected COVID-19 patients, particularly those with valve prostheses, including biological ones. Further studies are needed in order to shed light on the role of SARS-CoV-2 in thromboembolic phenomena and to confirm the most appropriate duration of anticoagulation therapy in selected patients.

COVID-19 and its implications for thrombosis and anticoagulation